European Pharmacopoeia method

DAICEL CORPORATION

Zolmitriptan :Impurity A



Column	: CHIRALPAK® AD-H 0.46cmΦ × 25cmL
Mobile phase	: Diethylamine *R* / 2-Propanol *R* / Methanol *R* / Heptane *R* = 0.1 / 10 / 15 / 75 (v / v / v / v)
Flow rate	: 1.0mL/min.
Injection volume	: 10μL
Column temperature	: 35℃
UV detection	: 285nm

System suitability

Reference solution (b):Dissolve 5.0 mg of the *Zomitriptan impurity A CRS* in the mobile phase and dilute to 5.0 mL with the mobile phase. To 1.0 mL of the solution add 1.0 mL of the test solution and dilute to 10.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 50.0 mL with the mobile phase.

Relative retention with reference to Zolmitriptan (retention time = about 7 min): impurity A = about 0.7

Reference solution (b)



	Requirement	Result
Resolution	Minimum 2.0 between the peaks due to impurity A and Zolmitriptan (reference solution (b))	6.4

For details of monograph, please check pharmacopoeia.